Why this is a milestone
Every GLP-1 obesity medicine before Foundayo required an injection, or (for Rybelsus, a diabetes-only pill) strict fasting rules. A daily tablet lowers two real barriers: needle aversion and dosing friction. Orforglipron was discovered by Chugai and licensed by Lilly.
How it compares with injectable tirzepatide
| Feature | Foundayo (orforglipron) | Injectable tirzepatide |
|---|---|---|
| Form | Once-daily pill | Weekly injection |
| Molecule | Single GLP-1 (non-peptide) | Dual GIP/GLP-1 |
| FDA status | Approved Apr 1, 2026 | Approved (Mounjaro/Zepbound) |
| Avg weight loss | ~11–12% (ATTAIN-1) | ~15–21% by dose (SURMOUNT-1) |
| Advertised cost | $25 insured / $149 self-pay | Varies |
What the data show
Who might prefer a pill
For people who avoid needles or dislike weekly injections, a daily tablet is a meaningful change. The trade-off is a daily habit and somewhat lower average weight loss than injectable tirzepatide — a reasonable exchange for many, less so for those seeking the largest result.
Market impact
Telehealth moved quickly: Ro signed a deal with Lilly in April 2026 to offer Foundayo. The approval does not change the status of compounded tirzepatide, which remains a separate, non-FDA-approved category. See our Foundayo vs compounded semaglutide comparison.
What we still do not know
Foundayo is new, so long-term real-world data are still accumulating: durability of weight loss, cardiovascular outcomes, and head-to-head performance against injectable tirzepatide. As with any GLP-1, gastrointestinal side effects are common early on. Anyone considering it should weigh cost and history with a clinician rather than assuming the newest option is automatically best.
Cost and access in practice
Real-world choice often comes down to coverage. Foundayo’s advertised insured price is low, but eligibility depends on your plan; the self-pay figure is higher though still below historic brand injectable list prices. Because plans treat obesity differently from diabetes, two people can face very different out-of-pocket costs for the same medicine. Price the pill, brand injectables, and any compounded route for your own situation rather than assuming one is always cheapest, and confirm current pricing directly before committing.
How it fits alongside tirzepatide
The arrival of an oral option does not make injectable tirzepatide obsolete. For patients prioritizing the largest average weight loss, injectable tirzepatide still leads; for those who have avoided treatment because of needles, the pill removes a genuine barrier. Some clinicians may start with a pill and escalate to an injectable if results plateau, or vice versa. The decision is individual and belongs with a licensed clinician who can weigh your history, tolerability, and goals rather than defaulting to whichever option is newest.
Frequently asked questions
Is Foundayo the same as tirzepatide?
No. Foundayo (orforglipron) is a single GLP-1 non-peptide small molecule; tirzepatide is an injectable dual GIP/GLP-1 agonist. Different medicines.
How much weight did people lose?
In ATTAIN-1, the highest dose produced roughly 11–12% average body-weight loss at 72 weeks (about 27 pounds among those who stayed on treatment) versus about 2% on placebo.
What does it cost?
Lilly advertises about $25/month with commercial coverage and $149/month self-pay via LillyDirect.
Does it replace injections?
It's an option, not a replacement. Injectable tirzepatide still tends to produce greater average weight loss; the pill trades some efficacy for convenience.
References
- Eli Lilly. FDA approves Foundayo (orforglipron). April 1, 2026.
- Drugs.com. Foundayo (orforglipron) approval history.
- Patient Care Online. FDA approves orforglipron, first oral GLP-1 for weight loss. 2026.